Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection-Reference-Cited by-同舟云学术

Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection

Published:2016-07-29 Issue:4 Volume:64 Page:1049-1056
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Abergel Armand¹,Metivier Sophie²,Samuel Didier³,Jiang Deyuan⁴,Kersey Kathryn⁴,Pang Phillip S.⁴,Svarovskaia Evguenia⁴,Knox Steven J.⁴,Loustaud-Ratti Veronique⁵,Asselah Tarik⁶

Affiliation:

1. Department of Hepatology and Gastroenterology; Centre Hospitalier Universitaire Estaing; Université d'Auvergne; UMR CNRS 6284 Clermont-Ferrand France

2. Department of Hepatology and Gastroenterology; Centre Hospitalier Universitaire Purpan; Toulouse France

3. Centre Hépato-Biliaire, Hôpital Paul Brousse, Assistance Publique-Hôpitaux de Paris, UMR-S 1193; Université Paris-Sud; INSERM U785 Villejuif France

4. Gilead Sciences, Inc; Foster City CA

5. Department of Hepatology and Gastroenterology; Centre Hospitalier Universitaire Limoges, U850 INSERM; Université de Limoges; Limoges France

6. Department of Hepatology, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris; Université Paris-Diderot and INSERM UMR1149; Clichy France

Funder

Gilead Sciences, Inc.

Publisher

Wiley

Subject

Hepatology

Reference32 articles.

1. Global epidemiology and genotype distribution of the hepatitis C virus;Gower;J Hepatol,2014

2. Towards realistic estimates of HCV incidence in Egypt;Breban;J Viral Hepat,2013